<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618874</url>
  </required_header>
  <id_info>
    <org_study_id>3866</org_study_id>
    <nct_id>NCT04618874</nct_id>
  </id_info>
  <brief_title>US NAB With ROSE Versus US FNAB With no ROSE</brief_title>
  <official_title>A RANDOMIZED TRIAL COMPARING PERCUTANEOUS ULTRASOUND-GUIDED NEEDLE ASPIRATION/BIOPSY WITH AND WITHOUT RAPID ON SITE EVALUATION IN PATIENTS WITH SUSPECTED SUPERFICIAL METASTASIS FROM LUNG CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, single center, controlled, randomized clinical trial with&#xD;
      two parallel arms in a 1:1 ratio. The objective of the study is to systematically assess the&#xD;
      influence of rapid on-site evaluation (ROSE) on the diagnostic yield for diagnosis and&#xD;
      molecular profiling, as well as on the safety, of pulmonologist-performed ultrasound-assisted&#xD;
      needle aspiration biopsy (US-NAB) of superficial lesions across different metastatic sites in&#xD;
      a series of consecutive patients with suspect locally advanced or advanced lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield for a tissue diagnosis</measure>
    <time_frame>20 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield for cancer genotyping</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield for PDL1 testing</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ROSE group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-assisted percutaneous needle aspiration with rapid on-site evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US NAB group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Ultrasound-assisted percutaneous needle aspiration without rapid on-site evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid on-site evaluation</intervention_name>
    <description>Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).</description>
    <arm_group_label>ROSE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known/suspected lung cancer&#xD;
&#xD;
          -  Presence of a suspected &quot;superficial&quot; metastasis at imaging studies (CT and/or PET)&#xD;
&#xD;
          -  Indication to tissue sampling for diagnosis, staging and/or molecular profiling&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Provision of a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness to consent&#xD;
&#xD;
          -  Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh&#xD;
             frozen plasma (FFP)&#xD;
&#xD;
          -  Use of antiplatelet (excluded aspirin) or anticoagulant drugs that cannot be&#xD;
             discontinued&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rocco Trisolini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario A. Gemelli, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanina Livi, MD</last_name>
    <phone>0039-328-3793744</phone>
    <email>vanina.livi@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rocco Trisolini, MD</last_name>
    <phone>0039-347-4251647</phone>
    <email>rocco.trisolini@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina Livi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Meena N, Bartter T. Ultrasound-guided Percutaneous Needle Aspiration by Pulmonologists: A Study of Factors With Impact on Procedural Yield and Complications. J Bronchology Interv Pulmonol. 2015 Jul;22(3):204-8. doi: 10.1097/LBR.0000000000000175.</citation>
    <PMID>26165890</PMID>
  </reference>
  <reference>
    <citation>Laursen CB, Naur TM, Bodtger U, Colella S, Naqibullah M, Minddal V, Konge L, Davidsen JR, Hansen NC, Graumann O, Clementsen PF. Ultrasound-guided Lung Biopsy in the Hands of Respiratory Physicians: Diagnostic Yield and Complications in 215 Consecutive Patients in 3 Centers. J Bronchology Interv Pulmonol. 2016 Jul;23(3):220-8. doi: 10.1097/LBR.0000000000000297.</citation>
    <PMID>27454475</PMID>
  </reference>
  <reference>
    <citation>Stigt JA, Oostdijk AH, Boers JE, van den Berg JW, Groen HJ. Percutaneous ultrasound-guided biopsies in the evaluation of thoracic tumours after PET-CT: a prospective diagnostic study. Respiration. 2012;83(1):45-52. doi: 10.1159/000330018. Epub 2011 Sep 16.</citation>
    <PMID>21934274</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Rapid on-site cytological examination</keyword>
  <keyword>Ultrasound-guided needle aspiration biopsy</keyword>
  <keyword>Lung adenocarcinoma</keyword>
  <keyword>Molecular profiling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

